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CONCLUSIONS: Regardless of LVERSUSF, prescribed
drug therapies at discharge were similar among patients
hospitalized for CHF in the hospital. Findings indicate a
need to better understand the role and actual implemen-
tation of guidelines that recommend customized CHF
drug therapy tailored to LVERSUSF.
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TREATED WITH HMG-COA REDUCTASE 
INHIBITORS: A RETROSPECTIVE STUDY
Nichol MB1, Jones J1, David A, Godolphin DA2, Bernstein E2
1University of Southern California, Los Angeles, CA, USA; 
2Equinox Group, Lexington, MA, USA
OBJECTIVES: The GOALS (Gauging Overall Attain-
ment of Lipid Standards) study, a retrospective chart re-
view of 1727 geographically diverse US adult patients
with hyperlipidemia, examined the extent to which pa-
tients met National Cholesterol Education Program
(NCEP) guidelines after treatment with various HMG-
CoA reductase inhibitors (“statins”).
METHODS: For this study 1500 physicians (family prac-
titioners and cardiologists) were randomly selected from
national lists. Forty-five physicians (37 FPs, 8 cardiolo-
gists) provided data on at least 40 hyperlipidemic pa-
tients. Each physician was asked to abstract data from
the medical charts of at least 10 atorvastatin patients, 10
simvastatin patients, and 20 patients who received any
statin between January 1996 and June 1998.
RESULTS: Patients were aged 20–96, 52% female, and
87% white. The most common primary prevention risk
factors were age (73%) and hypertension (58.8%). There
were no statistically significant differences in gender,
race, age at diagnosis, or source of reimbursement be-
tween patients using atorvastatin (n  195), simvastatin
(n  389), pravastatin (n  156), other statins (n  206),
or patients using various statins serially over the time pe-
riod (n  781). Similarly, there were no statistically sig-
nificant differences between the patients in these groups
in terms of secondary prevention risk factors (previous
myocardial infarction [MI], coronary artery disease
[CAD], peripheral vascular disease [PVD], or coronary
vascular disease [CVD]). Patients treated with atorva-
statin alone were significantly more likely to reach the
NCEP LDL-C treatment goal in a shorter time span (log-
rank test chi-square 52.20, p  0.0001).
CONCLUSIONS: This retrospective analysis reinforces
recent randomized trials suggesting hyperlipidemic pa-
tients using atorvastatin may be more likely to reach
NCEP LDL-C treatment goals faster than those using
other statins. Further analysis of patients using combina-
tion therapy is required.
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FORMULARY ANALYSIS OF ANGIOTENSIN II 
ANTAGONISTS IN A UK TEACHING HOSPITAL
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OBJECTIVE: The purpose of this study was to develop a
method of value analysis which would facilitate an objec-
tive comparison of available angiotensin II antagonists as
blood pressure lowering agents, in order to provide an
adaptable framework to allow for future clinical develop-
ments and new product introduction.
METHODS: The four angiotensin II antagonists avail-
able for analysis were candesartan, irbesartan, losartan,
and valsartan. The analysis was conducted under the aus-
pices of a team comprised of a cardiologist, a physician
and a pharmacist; the pharmacist was responsible for co-
ordination of the process. A nine-point selection criteria
set was developed and each criterion assigned a relative
weight value by the team. Each drug product was system-
atically evaluated against each criterion to generate a se-
ries of product-criterion scores. A total score for each
product was derived from the sum of product-criterion
score multiplied by the respective criterion weighted
value determined previously. The results were analyzed
and the model tested for sensitivity to parameter changes
where any doubts existed concerning the scoring process.
Results and outcomes were presented to the Drug and
Therapeutics Committee.
RESULTS: The initial analysis generated scores which
were similar for irbesartan (831) and candesartan (822).
These scores appeared to be significantly higher than
those obtained for valsartan (764) and losartan (706).
Following consideration of the impact of sensitivity tests
in the model, it had been previously decided that changes
in parameters reflecting efficacy were warranted and so
revised scores for candesartan (901) and irbesartan (871)
were calculated.
CONCLUSIONS: The results were presented to the Drug
and Therapeutics Committee and consequently the addi-
tion of candesartan and removal of losartan from the for-
mulary were formally approved.
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OBJECTIVE: The study purpose was to evaluate the
utility of a patient and prescriber program to increase the
use of antilipemics and/or estrogen in at-risk members
for CAD.
METHODS: Prescription claims from two employer
groups were screened to identify surrogate risk factors
for the development of CAD based on: nitrates, diabetic
claims, tobacco cessation products, and postmenopausal
women not receiving estrogen or cholesterol-lowering
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medications for 1Q98. Patients and providers were sent
educational material relating to identified risk and behav-
ioral and pharmacologic treatment options for the pre-
vention/management of CAD. The primary endpoint was
increased use of antilipemics and/or estrogen.
RESULTS: Of 60,241 patients, 3515 were identified with
at least one risk factor (at-risk CAD). Employer A had an
at-risk CAD prevalence rate of 9% (90.5% female/mean
age 60; men 55 years). Employer B had an at-risk preva-
lence rate of 16% (69.2% female/mean age 69; men 65
years). The predominant risk factor was postmenopausal
status (59%), followed by diabetes (33%) and nitrate
use (7.2%). Two or more risk factors were present in
12.3% and 13.8% of groups A and B, respectively. Post-
intervention, group A had a 9.2% increase in the utiliza-
tion of lipid-altering medications (55 on HMG-CoA in-
hibitors and 71 on estrogen). Group B witnessed an in-
crease of 5.6% (89 on HMGs and 32 on estrogen). Of
patients with three risk factors, group A had a 42% initi-
ation rate while group B a 33% rate.
CONCLUSIONS: An educational campaign toward pa-
tients and prescribers resulted in meaningful increases in
lipid-altering medication use. Patients with assumed
highest risk had the greatest increase in utilization. En-
hanced education is a cost-efficient method for improv-
ing utilization.
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OBJECTIVES: To assess clinical outcomes including 1)
National Cholesterol Education Panel (NCEP) Adult Treat-
ment Panel II goal attainment, and 2) percent low-density
lipoprotein cholesterol (LDL-C) reduction in a patient pop-
ulation treated with antihyperlipidemic medications.
METHODS: Medical charts were utilized to collect de-
mographic and clinical data from a random sample of
patients receiving lipid-lowering therapy at two managed
care sites in the southeastern United States from April
1997 to July 1998. Stratified univariate statistics and chi-
square tests were performed.
RESULTS: Data from 531 patients were analyzed, 287
(54%) of whom were women. The mean age at baseline
was 63.7 years. Drug utilization was as follows: 123
(22.8%) were being treated with atorvastatin, 69 (12.8%)
with fluvastatin, 42 (7.8%) with lovastatin, 158 (29.3%)
with pravastatin, 129 (23.9%) with simvastatin, and 10
(2%) with other agents. Due to small sample size, only
mean LDL-C reductions for each drug are presented. Mean
LDL-C reduction among patients receiving atorvastatin, flu-
vastatin, lovastatin, pravastatin, and simvastatin, respec-
tively, was 25.4%, 22.9%, 11.1%, 22.1%, and 26.2%. The
corresponding percentages of patients who met their NCEP
treatment targets were 57.3%, 50.8%, 34.2%, 50.7%, and
48%, respectively. The number of patients overall who met
their respective NCEP goals was 265 (50%).
CONCLUSIONS: Most agents showed similar activity
with regard to NCEP goal attainment. Further work will
be required to determine whether the observed similari-
ties in NCEP goal attainment will be reflected in other
outcome measures.
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OBJECTIVES: To estimate the cost per ischemic event
(death, nonfatal MI, and/or subsequent revasculariza-
tion) avoided over 6 months and to estimate the precision
of the cost-effectiveness ratio (CER).
METHODS: The sampling frame consisted of patients
undergoing a percutaneous revascularization procedure
at the University of Maryland Medical System to treat a
high-risk coronary lesion according to the American Col-
lege of Cardiology/American Heart Association morphol-
ogy classification system. Sixty-two patients treated with
abciximab were matched with 62 patients who were not
based on gender, diabetes, hyperlipidemia, and coronary
stenting. Three statistical methods were used to estimate
the precision of the CER: Taylor series; Fieller’s Theo-
rem; and confidence ellipsoids.
RESULTS: Abciximab-treated patients experienced a
41% reduction in the rate of ischemic events at 6 months
(16.1% versus 27.4%, p  0.128). The mean total cost of
inpatient treatment for abciximab-treated patients was
about $2460 higher than for patients not treated with ab-
ciximab. The point estimate for the CER was $21,789 per
ischemic event avoided at 6 months. Overall, confidence
intervals were relatively wide due to the non-significant
difference in the rate of ischemic events. Using the Taylor
series, the 90% CI ranged from $2097 to $41,480. A
90% CI could not be calculated using Fieller’s theorem.
However, the 80% CI ranged from $10,497 to $91,679.
Confidence ellipses provide an intuitive approach for vi-
sualizing the variability of differences in costs and effects
simultaneously.
CONCLUSIONS: Although institution-specific analyses
often lack power for hypothesis testing, the use of statis-
tical methods can provide decision-makers with a range
of CERs that are consistent with the data collected.
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A UK PRIMARY CARE DATABASE (UKPCD): UK 
MEDIPLUS IS A READILY AVAILABLE RESEARCH 
TOOL FOR DETERMINING THE PREVALENCE OF 
